Corbus Pharmaceuticals Holdings (CRBP) Return on Capital Employed (2014 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Return on Capital Employed of 75.77% for Q3 2025, down 4421.0% year-over-year from 1.75% in Q3 2024, and down 34.7% quarter-over-quarter from 56.25% in Q2 2025.
Corbus Pharmaceuticals Holdings (CRBP) Return on Capital Employed (2014 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Return on Capital Employed history runs 12 years deep, the most recent figure standing at 75.77% for Q3 2025.
- In Q3 2025, Return on Capital Employed fell 4421.0% year-over-year to 75.77%; the TTM figure through Sep 2025 stood at 75.77% (down 4421.0% YoY), while the FY2024 annual figure was 60.71%, up 23205.0% from the prior year.
- Return on Capital Employed for Q3 2025 stood at 75.77%, down from 56.25% in the prior quarter.
- The five-year high for Return on Capital Employed was 31.56% in Q3 2024, with the low at 11748.17% in Q4 2023.
- The 5-year median for Return on Capital Employed is 64.89% (2021), against an average of 707.97%.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed slumped 1167881 bps in 2023, then jumped 1171530 bps in 2024.
- Corbus Pharmaceuticals Holdings' Return on Capital Employed stood at 57.93% in 2021, then fell by 20 bps to 69.36% in 2022, then sank by 16838 bps to 11748.17% in 2023, then surged by 100 bps to 32.87% in 2024, then plunged by 130 bps to 75.77% in 2025.
- Business Quant data shows CRBP's Return on Capital Employed at 75.77% in Q3 2025, 56.25% in Q2 2025, and 43.2% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Corbus Pharmaceuticals Holdings | 127.63 Mn | -35.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -75.77% |
| Jun 30, 2025 | -56.25% |
| Mar 31, 2025 | -43.20% |
| Dec 31, 2024 | -32.87% |
| Sep 30, 2024 | -31.56% |
| Jun 30, 2024 | -35.00% |
| Mar 31, 2024 | -73.22% |
| Dec 31, 2023 | -11,748.17% |
| Sep 30, 2023 | -540.96% |
| Jun 30, 2023 | -142.07% |
| Mar 31, 2023 | -108.95% |
| Dec 31, 2022 | -69.36% |
| Sep 30, 2022 | -64.55% |
| Jun 30, 2022 | -61.07% |
| Mar 31, 2022 | -56.70% |
| Dec 31, 2021 | -57.93% |
| Sep 30, 2021 | -64.89% |
| Jun 30, 2021 | -77.84% |
| Mar 31, 2021 | -110.99% |
| Dec 31, 2020 | -182.84% |